Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference
NASDAQ, TSX: NVCN
VANCOUVER, Aug. 6, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present at the 38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8th at 12:30 pm ET being held in Boston, Massachusetts.
A live audio webcast of the presentation will be available on the Investors page of Neovasc's website at www.neovasc.com.
About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducertm (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiaratm (the "Tiara"), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET.
The presentation will...
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 10,...
Viridian Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming...
Intensity Therapeutics, Inc. ("Intensity" or "the Company") , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase...
Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier® in removing...
PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") , a specialty pharmaceutical company, today announced receipt of an Amendment Acknowledgment Letter ("AAL") for its Priority Original Abbreviated New Drug Application ("ANDA") for Ketamine...
